Clinical outcomes of < em > ALK < /em > + non-small cell lung cancer in Denmark

CONCLUSION: This study gives insights into the treatment and outcome of ALK+ NSCLC patients in Denmark and provides a real-world confirmation of the superior disease control provided by 2nd generation ALK-TKIs as compared to the 1st generation ALK-TKI crizotinib.PMID:37815923 | DOI:10.1080/0284186X.2023.2263153

Source: Acta Oncologica - October 10, 2023 Category: Cancer & Oncology Authors: Karin Holmskov Hansen Jakob Sidenius Johansen Edyta Maria Urbanska Peter Meldgaard Peter Hjorth-Hansen Charlotte Kristiansen Miroslaw Stelmach Eric Santoni-Rugiu Maiken Parm Ulh øi Anders Bondo Dydensborg Christina D ünweber Jon Lykkegaard Andersen Source Type: research